US Market Report for Powered Morcellators 2017 - MedCore
General Report Contents
Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
Market Drivers & Limiters for each chapter segment
Competitive Analysis for each chapter segment
Section on recent mergers & acquisitions
Laparoscopic morcellators are used during laparoscopic supracervical hysterectomy (LSH) and laparoscopic myomectomy (LM). Total laparoscopic hysterectomy (TLH) and laparoscopically assisted vaginal hysterectomy (LAVH) are less frequently performed due to disadvantages such as increased blood loss, slower recovery and post-surgery complications. LSH involves the removal of the uterus, while TLH involves the removal of both the uterus and the cervix. Physicians recommend LSH or TLH based on the patient’s degree of disease progression. The majority of hysterectomies are performed in order to remove a uterus containing fibroids, benign growths in the uterus that can cause pain, bleeding, and a variety of other symptoms. Growth in the laparoscopic morcellator market is more associated with rates of LSH than it is associated with rates of TLH.
Laparoscopic morcellators are targeted towards three categories of minimally invasive surgery (MIS): general surgery, urology surgery and most commonly in gynecological surgery. Traditionally, laparoscopic resection devices are employed to excise malignant tissue masses from site of operation; however, with the reduction in the size of laparoscopic instruments used in MIS, removal of large-mass malignant tissues by way of small incisions can be cumbersome.